Gynecologic Cancer
From the Journals
Most Targeted Cancer Drugs Lack Substantial Clinical Benefit
Researchers assess validity of the molecular targets and clinical benefits of genome-targeted cancer drugs approved in the United States from 2015...
Conference Coverage
No Routine Cancer Screening Option? New MCED Tests May Help
CanScan, MERCURY, and OncoSeek can detect a range of cancers and recognize the tissue of origin with high accuracy.
Conference Coverage
Ovarian Cancer: Another Promising Target for Liquid Biopsy
A test under development “looks very sensitive for detecting ovarian cancer early.”
From the Journals
Oncologists Voice Ethical Concerns Over AI in Cancer Care
Researchers ask 204 oncologists from 37 states for their views on the ethical implications of using AI for cancer care.
Conference Coverage
Circulating Tumor DNA Predicts Early Treatment Response in Patients With HER2-Positive Cancers
New study results suggest ctDNA dynamics provide an early window into predicting response to targeted therapies in patients with HER2-altered...
Conference Coverage
Repeat MCED Testing May ID Early-Stage and Unscreened Cancers
Eight of 26 patients with cancer signals detected through MCED had cancer.
From the Journals
Less Than 50% of Accelerated Approvals Show Clinical Benefit
Researchers review 46 cancer drugs granted accelerated approvals between 2013 and 2017.
From the Journals
Virtual Reality Brings Relief to Hospitalized Patients With Cancer
Patients were randomized to receive either 10 minutes of immersive VR distraction therapy or 10 minutes of two-dimensional guided imagery...
Commentary
A Banned Chemical That Is Still Causing Cancer
This carcinogen ‘is still around: in our soil, in our food, and in our blood.’
Conference Coverage
Money, Ethnicity, and Access Linked to Cervical Cancer Disparities
An online analytic tool provides visual evidence of the geographic and demographic disparities in incident and recurrent/metastatic cervical...
From the Journals
Active Surveillance for Cancer Doesn’t Increase Malpractice Risk
Researchers identify malpractice trends involving active surveillance related to thyroid, prostate, kidney, and...